News Digest / Ticker: HIK.L

Ticker: HIK.L

07:31am, Monday, Oct 06, 2025

GSK to File Leucovorin Autism Label After FDA's ~40‑Case Review - 4-6 Month Fast‑Track Could Lift Sales, Squeeze Hikma

FDA asks GSK to refile branded leucovorin for cerebral folate deficiency, fast‑tracking a label change that could boost prescriptions and generic sales (Hikma). Traders watch insurer coverage and a precedent for quicker repurposing.